ACAD up +4.25% percent Today $ACAD High is at 28.40 and the Low 27.11 with current volume of 242,005.
Recent News posted below.
Acadia Pharmaceuticals Inc ACAD other info.
http://investorshangout.com/Acadia-Pharmaceut...CAD-53204/
ACAD Acadia Pharmaceuticals Inc Recent Headline News
Acadia Pharmaceuticals Earnings In Retrospect: Down 3.8% in the Last 7 Days (ACAD)
Comtex SmarTrend(R) - Mon Nov 17, 2:57PM CST
7 days ago, on November 10th, 2014, Acadia Pharmaceuticals (NASDAQ:ACAD) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $72.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.25 per share on sales of $15.0 thousand, missing EPS estimates by $0.03 and matching revenue estimates. Shares of Acadia Pharmaceuticals have slipped from $28.21 to $27.14, representing a loss of 3.8%, since the company reported earnings 7 days ago.
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
Business Wire - Thu Nov 13, 8:01AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Thursday, November 20, 2014, at 9:20 a.m. GMT in London.
ACAD: 27.93 (+0.85)
Watch for Acadia Pharmaceuticals to Potentially Rebound After Falling 2.52% Yesterday
Comtex SmarTrend(R) - Tue Nov 11, 4:44PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $26.57 to a high of $28.19. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $27.03 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals' (ACAD) CEO Uli Hacksell on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:51PM CST
ACAD: 27.93 (+0.85)
Acadia misses 3Q profit forecasts
Automated Insights - Mon Nov 10, 4:13PM CST
SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Monday reported a loss of $24.8 million in its third quarter.
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals (ACAD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 3:55PM CST
ACAD: 27.93 (+0.85)
ACADIA Pharma misses by $0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:02PM CST
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID(TM) NDA Submission
Business Wire - Mon Nov 10, 3:01PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2014 and provided an update on the timing of its NUPLAZID(TM) (pimavanserin) New Drug Application (NDA) submission.
ACAD: 27.93 (+0.85)
'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin
at The Street - Wed Nov 05, 5:00AM CST
Cramer says Leucadia National is too dangerous for him, hold on to General Electric but wait on ConocoPhillips and Hess.
LUK: 24.49 (+0.35), LMT: 186.19 (+0.68), GE: 26.92 (+0.31), ACAD: 27.93 (+0.85), HES: 82.39 (+1.15), COP: 71.61 (+0.19)
Cramer's Lightning Round - Wait To Take A Stand On Oil (11/4/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Nov 05, 4:54AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday November 4. Bullish Calls: General Electric (NYSE: GE ): "My charitable trust has been back and forth. It has been wallpaper. GE is a boring...
LUK: 24.49 (+0.35), LMT: 186.19 (+0.68), ACAD: 27.93 (+0.85), GE: 26.92 (+0.31), HES: 82.39 (+1.15), COP: 71.61 (+0.19)
Jim Cramer's 'Mad Money' Recap: Why Are Money Managers Making Things So Complicated?
at The Street - Tue Nov 04, 7:31PM CST
The smart money is buying, not selling, on the current low oil prices, Cramer insists.
LUK: 24.49 (+0.35), GPRO: 85.20 (+3.70), TMST: 37.39 (+0.19), LMT: 186.19 (+0.68), GE: 26.92 (+0.31), ACAD: 27.93 (+0.85), HES: 82.39 (+1.15), FB: 74.29 (+0.05), COP: 71.61 (+0.19), GOOGL: 546.05 (-0.59), TWTR: 40.07 (-0.40)
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
Business Wire - Mon Nov 03, 8:02AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2014 on Monday, November 10, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Monday, November 10, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
ACAD: 27.93 (+0.85)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.26 (+0.03), ACAD: 27.93 (+0.85), HALO: 8.67 (+0.11), ISIS: 49.90 (+0.89), NSPH: 0.43 (-0.01)
Global Psychosis Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3lmd7/psychosis_global) has announced the addition of the "Psychosis Global Clinical Trials Review, H2, 2014" report to their offering. Psychosis Global Clinical Trials Review, H2, 2014 provides elemental information and data relating to the clinical trials on Psychosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Psychosis. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Psychosis Therapeutics Clinical Trials - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Pfizer Inc. - Otsuka Holdings Co., Ltd. - ZonMw - North Shore-Long Island Jewish Health System, Inc. - Acadia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government - Department of Health, South Africa - Yale University - U.S. Department of Veterans Affairs - The University of Hong Kong - Maastricht University - Centre for Addiction and Mental Health - University of British Columbia - Melbourne Health - University of Cologne - New York State Psychiatric Institute For more information visit http://www.researchandmarkets.com/research/q3...sis_global
JNJ: 108.88 (+0.58), ACAD: 27.93 (+0.85), PFE: 30.66 (+0.34), AZN: 73.72 (+1.22), LLY: 67.93 (+0.64)
3 Stocks I'll Buy if the Market Crashes
George Budwell, The Motley Fool - Motley Fool - Mon Oct 20, 12:01PM CDT
After a monstrous bull run of late, the stock market finally started to pullback. The Nasdaq Biotechnology Index , for instance, fell by nearly 7% last week alone: Even so, it's important to keep the magnitude of this week's drop in...
ACAD: 27.93 (+0.85), GILD: 103.00 (+2.56), SHPG: 209.23 (+3.24), NPSP: 30.88 (+0.97), IBB: 295.00 (+6.16), ABBV: 65.94 (+0.90)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 305.37 (+2.95), MNOV: 2.87 (-0.13), CHTP: 6.52 (-0.03), ADMS: 14.63 (-0.17), ACOR: 34.63 (+0.53), BCLI: 3.42 (+0.04), BSX: 13.48 (+0.10), IPXL: 29.44 (+0.73), AVNR: 13.50 (+0.25), ACAD: 27.93 (+0.85), CVTS: (), MRK: 59.91 (+0.45), TEVA: 57.38 (+0.14), PRTA: 23.00 (+0.92), PRAN: 1.66 (-0.02), FOLD: 6.34 (-0.36), CUR: 2.87 (+0.05)
Cramer's Lightning Round - You Get Good News From Regeneron (10/16/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Oct 17, 5:08AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday October 16. Bullish Calls: Regeneron (NASDAQ: REGN ): "I like Regeneron. It has a backer, it has new drugs, it's the future. That is where...
72.41 (+0.25), ACAD: 27.93 (+0.85), PXD: 167.16 (+2.12), XOM: 95.13 (+0.02), REGN: 411.00 (+11.35)
TNK, SD, CBNJ, MYRG, GCA, ACAD Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Teekay Tankers Ltd (NYSE:TNK), SANDRIDGE ENERGY, INC. (NYSE:SD), Cape Bancorp Inc (NASDAQ:CBNJ), MYR GROUP, INCORPORATION (NASDAQ:MYRG), GLOBAL CASH ACCESS HOLDINGS, INC. (NYSE:GCA), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SD: 3.76 (+0.05), ACAD: 27.93 (+0.85), CBNJ: 9.28 (+0.06), MYRG: 26.18 (-0.02), GCA: 7.20 (+0.06), TNK: 4.28 (+0.05)
Critical Alerts For FuelCell Energy, VeriFone Systems, Universal Display Corporation, Synaptics Incorporated and ACADIA Pharmaceuticals Released By InvestorsObserver
PR Newswire - Fri Sep 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCEL, PAY, OLED, SYNA and ACAD.
FCEL: 1.76 (+0.10), ACAD: 27.93 (+0.85), OLED: 27.76 (+0.80), SYNA: 61.88 (+1.56), PAY: 37.09 (+0.71)
Recent News posted below.
Acadia Pharmaceuticals Inc ACAD other info.
http://investorshangout.com/Acadia-Pharmaceut...CAD-53204/
ACAD Acadia Pharmaceuticals Inc Recent Headline News
Acadia Pharmaceuticals Earnings In Retrospect: Down 3.8% in the Last 7 Days (ACAD)
Comtex SmarTrend(R) - Mon Nov 17, 2:57PM CST
7 days ago, on November 10th, 2014, Acadia Pharmaceuticals (NASDAQ:ACAD) reported its earnings. Analysts, on average, expected a loss of $0.22 per share on sales of $72.0 thousand. Acadia Pharmaceuticals actually reported a loss of $0.25 per share on sales of $15.0 thousand, missing EPS estimates by $0.03 and matching revenue estimates. Shares of Acadia Pharmaceuticals have slipped from $28.21 to $27.14, representing a loss of 3.8%, since the company reported earnings 7 days ago.
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
Business Wire - Thu Nov 13, 8:01AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies 2014 Global Healthcare Conference on Thursday, November 20, 2014, at 9:20 a.m. GMT in London.
ACAD: 27.93 (+0.85)
Watch for Acadia Pharmaceuticals to Potentially Rebound After Falling 2.52% Yesterday
Comtex SmarTrend(R) - Tue Nov 11, 4:44PM CST
Acadia Pharmaceuticals (NASDAQ:ACAD) traded in a range yesterday that spanned from a low of $26.57 to a high of $28.19. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $27.03 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals' (ACAD) CEO Uli Hacksell on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:51PM CST
ACAD: 27.93 (+0.85)
Acadia misses 3Q profit forecasts
Automated Insights - Mon Nov 10, 4:13PM CST
SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Monday reported a loss of $24.8 million in its third quarter.
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals (ACAD) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 3:55PM CST
ACAD: 27.93 (+0.85)
ACADIA Pharma misses by $0.03
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:02PM CST
ACAD: 27.93 (+0.85)
ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID(TM) NDA Submission
Business Wire - Mon Nov 10, 3:01PM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the third quarter ended September 30, 2014 and provided an update on the timing of its NUPLAZID(TM) (pimavanserin) New Drug Application (NDA) submission.
ACAD: 27.93 (+0.85)
'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin
at The Street - Wed Nov 05, 5:00AM CST
Cramer says Leucadia National is too dangerous for him, hold on to General Electric but wait on ConocoPhillips and Hess.
LUK: 24.49 (+0.35), LMT: 186.19 (+0.68), GE: 26.92 (+0.31), ACAD: 27.93 (+0.85), HES: 82.39 (+1.15), COP: 71.61 (+0.19)
Cramer's Lightning Round - Wait To Take A Stand On Oil (11/4/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Nov 05, 4:54AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday November 4. Bullish Calls: General Electric (NYSE: GE ): "My charitable trust has been back and forth. It has been wallpaper. GE is a boring...
LUK: 24.49 (+0.35), LMT: 186.19 (+0.68), ACAD: 27.93 (+0.85), GE: 26.92 (+0.31), HES: 82.39 (+1.15), COP: 71.61 (+0.19)
Jim Cramer's 'Mad Money' Recap: Why Are Money Managers Making Things So Complicated?
at The Street - Tue Nov 04, 7:31PM CST
The smart money is buying, not selling, on the current low oil prices, Cramer insists.
LUK: 24.49 (+0.35), GPRO: 85.20 (+3.70), TMST: 37.39 (+0.19), LMT: 186.19 (+0.68), GE: 26.92 (+0.31), ACAD: 27.93 (+0.85), HES: 82.39 (+1.15), FB: 74.29 (+0.05), COP: 71.61 (+0.19), GOOGL: 546.05 (-0.59), TWTR: 40.07 (-0.40)
ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
Business Wire - Mon Nov 03, 8:02AM CST
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2014 on Monday, November 10, 2014, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Monday, November 10, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA's financial results and development programs.
ACAD: 27.93 (+0.85)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 3.26 (+0.03), ACAD: 27.93 (+0.85), HALO: 8.67 (+0.11), ISIS: 49.90 (+0.89), NSPH: 0.43 (-0.01)
Global Psychosis Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q3lmd7/psychosis_global) has announced the addition of the "Psychosis Global Clinical Trials Review, H2, 2014" report to their offering. Psychosis Global Clinical Trials Review, H2, 2014 provides elemental information and data relating to the clinical trials on Psychosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Psychosis. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Psychosis Therapeutics Clinical Trials - Johnson & Johnson - AstraZeneca PLC - Eli Lilly and Company - Pfizer Inc. - Otsuka Holdings Co., Ltd. - ZonMw - North Shore-Long Island Jewish Health System, Inc. - Acadia Pharmaceuticals Inc. Clinical Trial Overview of Top Institutes / Government - Department of Health, South Africa - Yale University - U.S. Department of Veterans Affairs - The University of Hong Kong - Maastricht University - Centre for Addiction and Mental Health - University of British Columbia - Melbourne Health - University of Cologne - New York State Psychiatric Institute For more information visit http://www.researchandmarkets.com/research/q3...sis_global
JNJ: 108.88 (+0.58), ACAD: 27.93 (+0.85), PFE: 30.66 (+0.34), AZN: 73.72 (+1.22), LLY: 67.93 (+0.64)
3 Stocks I'll Buy if the Market Crashes
George Budwell, The Motley Fool - Motley Fool - Mon Oct 20, 12:01PM CDT
After a monstrous bull run of late, the stock market finally started to pullback. The Nasdaq Biotechnology Index , for instance, fell by nearly 7% last week alone: Even so, it's important to keep the magnitude of this week's drop in...
ACAD: 27.93 (+0.85), GILD: 103.00 (+2.56), SHPG: 209.23 (+3.24), NPSP: 30.88 (+0.97), IBB: 295.00 (+6.16), ABBV: 65.94 (+0.90)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 305.37 (+2.95), MNOV: 2.87 (-0.13), CHTP: 6.52 (-0.03), ADMS: 14.63 (-0.17), ACOR: 34.63 (+0.53), BCLI: 3.42 (+0.04), BSX: 13.48 (+0.10), IPXL: 29.44 (+0.73), AVNR: 13.50 (+0.25), ACAD: 27.93 (+0.85), CVTS: (), MRK: 59.91 (+0.45), TEVA: 57.38 (+0.14), PRTA: 23.00 (+0.92), PRAN: 1.66 (-0.02), FOLD: 6.34 (-0.36), CUR: 2.87 (+0.05)
Cramer's Lightning Round - You Get Good News From Regeneron (10/16/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Oct 17, 5:08AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday October 16. Bullish Calls: Regeneron (NASDAQ: REGN ): "I like Regeneron. It has a backer, it has new drugs, it's the future. That is where...
72.41 (+0.25), ACAD: 27.93 (+0.85), PXD: 167.16 (+2.12), XOM: 95.13 (+0.02), REGN: 411.00 (+11.35) TNK, SD, CBNJ, MYRG, GCA, ACAD Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Teekay Tankers Ltd (NYSE:TNK), SANDRIDGE ENERGY, INC. (NYSE:SD), Cape Bancorp Inc (NASDAQ:CBNJ), MYR GROUP, INCORPORATION (NASDAQ:MYRG), GLOBAL CASH ACCESS HOLDINGS, INC. (NYSE:GCA), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SD: 3.76 (+0.05), ACAD: 27.93 (+0.85), CBNJ: 9.28 (+0.06), MYRG: 26.18 (-0.02), GCA: 7.20 (+0.06), TNK: 4.28 (+0.05)
Critical Alerts For FuelCell Energy, VeriFone Systems, Universal Display Corporation, Synaptics Incorporated and ACADIA Pharmaceuticals Released By InvestorsObserver
PR Newswire - Fri Sep 26, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FCEL, PAY, OLED, SYNA and ACAD.
FCEL: 1.76 (+0.10), ACAD: 27.93 (+0.85), OLED: 27.76 (+0.80), SYNA: 61.88 (+1.56), PAY: 37.09 (+0.71)
